|
Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen |
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Exelixis; MSD; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; MSD; Pfizer; Roche |
Speakers' Bureau - Ipsen; Janssen; MSD; Roche |
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; Pfizer; PharmaMar; Roche |
Speakers' Bureau - Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer |
|
|
Consulting or Advisory Role - Exelixis; Novartis; Roche |
|
|
|
Stock and Other Ownership Interests - Biogen; Ipsen |
|
|
|
Stock and Other Ownership Interests - Ipsen |
|
|
Employment - Ipsen; Sanofi Pasteur |
Stock and Other Ownership Interests - Ipsen |
|
|
|
Stock and Other Ownership Interests - Exelixis |
|
|
Honoraria - Alexion Pharmaceuticals; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate |
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate |
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst) |